SALT LAKE CITY, Aug. 8, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced an expanded partnership with Contexture, a nonprofit, regional health information exchange organization that works to drive health data interoperability. Contexture supports the flow of health information between thousands of physician practices, hospitals, long-term care facilities, labs, radiology ...

Health Catalyst (HCAT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this provider of data analytics for the health care industry would post earnings of $0.03 per share when it actually produced earnings of $0.05, delivering a surprise of ...

"This financing is an important milestone for Health Catalyst and its shareholders. The Credit Facility not only assists with refinancing our existing convertible notes, but also provides flexibility and additional non-dilutive capital for us to continue to proactively pursue meaningful organic and inorganic growth opportunities, and to continue to act as a consolidation platform for our clients, integrating compelling technologies within our five areas of focus, which we believe positions us well to create ...

Healthcare portfolios include telehealth stocks, notably after the COVID-19 pandemic, which increased global telemedicine usage, demonstrating their importance for lockdowns and other social isolation scenarios. A Dana-Farber Cancer Institute study also indicated that telemedicine may considerably cut cancer treatment greenhouse gas emissions. Under these circumstances, telehealth stocks will only gain favor with the investing community. That's why we'll explore three undervalued telehealth stocks, each wit ...

SALT LAKE CITY, June 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has successfully completed its acquisition of Carevive Systems ("Carevive"), a leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. Oncology providers and life science researchers use Carevive's flagship platform and/or ...

Core Insights - Health Catalyst, Inc. is actively participating in upcoming investor conferences, indicating a focus on investor engagement and communication [1] - The company is a leading provider of data and analytics technology and services specifically tailored for healthcare organizations [2] Company Overview - Health Catalyst aims to drive significant, measurable improvements in healthcare through data-informed decision-making [2] - The company utilizes a cloud-based data platform that integrates data from over 100 million patient records, encompassing trillions of facts [2] - Health Catalyst's offerings include analytics software and professional services to help clients achieve clinical, financial, and operational enhancements [2] Upcoming Events - Jason Alger, CFO, and Jack Knight, VP of Investor Relations, will participate in the Stifel Cross Sector Insight Conference on June 4, 2024, at 9:45am ET [1] - The company will also present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, at 8:40am ET [1]

Investors might want to bet on Health Catalyst (HCAT) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. 12 Month EPS Current-Quarter Estimate Revisions The earnings estimate of $0.09 per share for the current quarter represents a change of +80% from the number reported a year ago. The Zacks Consensus Estimate for Health Catalyst has increas ...

Shares of Health Catalyst (HCAT) have gained 11.6% over the past four weeks to close the last trading session at $6.73, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $11.79 indicates a potential upside of 75.2%. The average comprises 14 short-term price targets ranging from a low of $8 to a high of $16, with a standard deviation of $2.72. While the lowest estimate indicates an ...

SALT LAKE CITY, May 21, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of Health Catalyst Ignite®, a next-generation healthcare data and analytics ecosystem that combines best-in-class technologies, healthcare-specific data models, self-service tools, and industry expertise in one modern environment. Today's health systems face significant challenges in navig ...

Health Catalyst (HCAT) reported $74.72 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 1.2%. EPS of $0.05 for the same period compares to $0.05 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $74.81 million, representing a surprise of -0.11%. The company delivered an EPS surprise of +66.67%, with the consensus EPS estimate being $0.03.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wal ...